Handelsavisen
prelaunch
Companies Healthcare CWEB.TO
CW
CWEB.TO Toronto Stock Exchange Pharmaceuticals

Charlotte's Web Holdings Inc

C$0,54
Open in Charts → Attach watcher ⌖
CAD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
-69,0 %
ROE
-20,6 %
Net margin
-79,5 %
Debt / equity
0,92
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Charlotte's Web Holdings Inc develops and commercializes hemp-based pharmaceutical and consumer products, targeting chronic pain, inflammation, and other medical conditions.

Business. Charlotte's Web Holdings Inc (CWEB.TO) is a pharmaceutical company engaged in the research, development, and commercialization of cannabis-based products. The firm is headquartered in Canada and is primarily listed on the Toronto Stock Exchange. As specific operating segment and geographic data are not provided, the company is described at the industry level within the Healthcare sector.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
-20,6 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning CWEB.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to CWEB.TO. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Charlotte's Web Holdings Inc (CWEB.TO) is a pharmaceutical company engaged in the research, development, and commercialization of cannabis-based products. The firm is headquartered in Canada and is primarily listed on the Toronto Stock Exchange. As specific operating segment and geographic data are not provided, the company is described at the industry level within the Healthcare sector.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    Charlotte's Web Holdings Inc operates with a debt-to-equity ratio of 0.92 and a current ratio of 3.48, indicating a moderate liquidity position with sufficient short-term assets to cover liabilities. However, the company's operating cash flow is negative at -7.18 million USD, and free cash flow is also negative at -9.20 million USD, signaling potential challenges in generating positive cash from operations.

    Profitability metrics show a return on equity of -20.64% and a return on assets of -6.8%, both significantly below industry norms for pharmaceutical firms, which typically exhibit positive returns. The company reported a net loss of 9.63 million USD and an operating loss of 8.37 million USD, highlighting a lack of profitability.

    The company's revenue is concentrated in a single business segment focused on hemp-based pharmaceuticals and consumer products, with no disclosed geographic diversification. This concentration increases exposure to regulatory and market risks in the cannabis industry.

    Looking ahead, the company is projected to see a decline in revenue, with a negative outlook for the current fiscal year. Historical revenue data shows a decrease from 12.12 million USD in the latest period, and no significant growth drivers are currently evident.

    The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after accounting for total debt, which could constrain its ability to fund operations without external financing.

    Recent filings and transcripts have not disclosed any major strategic shifts or new product launches. The company continues to focus on its core hemp-based product line, with no indication of diversification or expansion into new markets.

    Key takeaways
    • The company has a negative return on equity and return on assets, indicating poor profitability.
    • Liquidity is moderate, with a current ratio of 3.48, but operating and free cash flows are negative.
    • Revenue is concentrated in a single business segment, increasing exposure to market and regulatory risks.
    • The company is projected to see a decline in revenue, with no significant growth drivers identified.
    • Liquidity risk is medium, and dilution risk is low, but the company's net cash position is negative after accounting for total debt.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 5

    Operating income improved 36.6% year-over-year, signaling a meaningful reduction in operational losses for the fiscal year.

    Free cash flow improved by 11.3% year-over-year, indicating a slight stabilization in cash burn rates.

    Dilution risk is assessed as low, suggesting limited immediate threat to shareholder equity from share issuance.

    Credit risk is rated low, implying manageable default probabilities despite the company's ongoing financial challenges.

    Revenue remained relatively stable with only a 0.5% year-over-year change, showing some top-line resilience.

    BEAR CASE · 3

    The company posted a net loss of $29.7 million in the latest fiscal year, continuing its unprofitable trajectory.

    Debt-to-equity ratio of 0.92 places the company in the bottom quartile of its peer group.

    Liquidity risk is assessed as medium, raising concerns about the company's ability to meet short-term obligations.

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2026-03-31
    Q4 2025 · Quarter highlights

    Revenue $13.3M, +5,2% YoY; Operating income −2,6% YoY.

    Revenue$13.3M+5,2 % YoY
    Operating income-$5.6M−2,6 % YoY
    Net income-$11.4M−239,2 % YoY
    Free cash flow-$9.6M−766,2 % YoY
    EPS
    Operating cash flow-$14.1M+33,6 % YoY
    Financials
    Income statement
    Revenue$13.3M
    Gross profit$5.0M
    Operating income-$5.6M
    Net income-$11.4M
    Margins
    Gross margin37.5%
    Operating margin-42.0%
    Net margin-85.7%
    FCF margin-72.4%
    Balance sheet
    Total assets$75.3M
    Total liabilities$77.3M
    Total equity-$2.0M
    Cash & equivalents$8.0M
    Long-term debt$50.8M
    Cash flow
    Operating cash flow-$14.1M
    CapEx-$549.0k
    Free cash flow-$9.6M
    SBC
    P&L flow · revenue → net income
    Revenue $13.3MOperating costs $18.9MTax $5.8MNet income $11.4M
    Highlights
    • Revenue $13.3M, +5,2% YoY
    • Operating income −2,6% YoY
    • Net income −239,2% YoY
    • Free cash flow −766,2% YoY
    • Net margin -85.7%

    Valuation TTM

    Market price
    C$0,54
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    C$46.7M
    Net cash
    -C$4.2M
    Current ratio
    3.5
    Debt / equity
    0.9
    ROA
    -6.8%
    ROE
    -20.6%
    Cash conversion
    75.0%
    CapEx / revenue
    -17.0%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-69,0 %Bottom quartile
    Net Margin-79,5 %Bottom quartile
    ROE-20,6 %Bottom quartile
    Capex / Rev-17,0 %Bottom quartile
    D/E0,92Bottom quartile
    Cash Conv0,75Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Charlotte's Web Holdings Inc Market data — financials · 2026-05-27
    • Charlotte's Web Holdings Inc Market data — analyst estimates · 2026-05-27

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    1.7Mshares short+9.1% vs prior
    2.44days to cover
    53.0%short of daily vol
    28.5Kfails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    CWEB.TOCanonical
    Toronto Stock Exchange · CAD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-03-31 07:12 UTCEARNINGSQuarterly results — Q4 2025 Revenue USD 13.3M · Net USD -11.4M
    2026-03-31 07:12 UTCEARNINGSAnnual results — FY 2026 Revenue USD 49.9M · Net USD -29.7M
    2025-03-19 07:17 UTCEARNINGSQuarterly results — Q4 2024 Revenue USD 12.7M · Net USD -3.4M
    2025-03-19 07:17 UTCEARNINGSAnnual results — FY 2025 Revenue USD 49.7M · Net USD -29.8M
    2024-11-14 07:10 UTCEARNINGSQuarterly results — Q3 2024 Revenue USD 12.6M · Net USD -5.8M
    2024-08-08 07:10 UTCEARNINGSQuarterly results — Q2 2024 Revenue USD 12.3M · Net USD -11.1M
    2024-05-08 07:10 UTCEARNINGSQuarterly results — Q1 2024 Revenue USD 12.1M · Net USD -9.6M
    2024-03-21 07:11 UTCEARNINGSAnnual results — FY 2024 Revenue USD 63.2M · Net USD -23.8M
    2023-03-23 06:57 UTCEARNINGSAnnual results — FY 2023 Revenue USD 74.1M · Net USD -59.3M
    2022-03-24 07:00 UTCEARNINGSAnnual results — FY 2022 Revenue USD 96.1M · Net USD -137.7M
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage